Hahn NM, Powles T, Massard C, et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). J Clin Oncol. 2017;35 (suppl; abstr 4525).
Combinatie JAK-remmer en anti-PD-1 bij gemetastaseerd NSCLC
sep 2024 | Immuuntherapie, Longoncologie